Dr. Shaibani of Baylor College of Medicine has no relevant financial relationships to disclose.)
Dr. Weimer of Columbia University has received consulting fees from Roche.)
This article includes discussion of diabetic amyotrophy, Bruns-Garland syndrome, diabetic lumbosacral radiculoplexus neuropathy, diabetic mononeuritis multiplex, diabetic polyradiculopathy, and proximal diabetic neuropathy. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.
Diabetic amyotrophy is predominantly a motor condition that involves various elements of the lumbosacral plexus, particularly those related to the femoral nerve. It usually presents acutely as unilateral thigh pain followed by weakness and later wasting in the anterior thigh muscles. Diabetic amyotrophy typically occurs in older patients with type 2 diabetes. An immune-mediated epineurial microvasculitis has been demonstrated in nerve biopsies. When severe and progressive, predominantly motor polyneuropathy develops in diabetic patients, one must also consider chronic inflammatory demyelinating polyradiculoneuropathy. In this article, the authors discuss recent studies that have provided novel insights into the pathogenesis of diabetic amyotrophy, leading to the establishment of formal clinical trials of mechanistically relevant therapies like immunoglobulin and methylprednisolone.
• Diabetic amyotrophy, which presents usually as unilateral thigh pain followed by weakness, can be painless.
• The diabetic amyotrophy mechanism is ischemic injury possibly secondary to microvasculitis.
• It is important, and sometimes difficult, to differentiate diabetic amyotrophy from chronic inflammatory demyelinating polyradiculoneuropathy.
Historical note and terminology
The syndrome of wasting and weakness of the pelvifemoral muscles associated with diabetes mellitus was originally described by Ludwig Bruns in 1890 (Bruns 1890). Many years later, Garland and Taverner expanded the description (Garland and Taverner 1953) and later coined the term “diabetic amyotrophy” (Garland 1955). Since the inception of the term, its nomenclature has been controversial based on its variable presentations (proximal versus proximal and distal; asymmetric versus symmetric), onset (abrupt versus insidious), and different electrophysiological and biopsy findings described. Skeptics have challenged the term “diabetic amyotrophy” because it erroneously implies a primary muscle disorder as well as the term “proximal diabetic neuropathy” because distal weakness is often present as well. Disagreements regarding pathogenesis (metabolic versus ischemia) have prompted some authors to suggest that the process is a clinical continuum of diabetic neuropathy rather than a distinct clinical entity (Asbury 1977). Similarities to other symptom complexes have produced newer and more descriptive terms such as “diabetic lumbosacral radiculoplexus neuropathy” and “diabetic mononeuritis multiplex.” Considerable evidence that diabetic amyotrophy is a distinct clinical entity with a defined clinical spectrum and pathophysiology has emerged over the last several years.
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.